

# Q2 2022 Financial Results

# Appendix

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended		Six Months Ended	
	June 30, 2022	June 30, 2021	June 30, 2022	June 30, 2021
<b>Reconciliation of GAAP to Non-GAAP research and development:</b>				
GAAP Research and development	\$ 205,712	\$ 182,635	\$ 375,605	\$ 368,534
Less: Stock-based compensation expenses	(10,638)	(13,086)	(22,255)	(37,461)
Non-GAAP Research and development	<u>\$ 195,074</u>	<u>\$ 169,549</u>	<u>\$ 353,350</u>	<u>\$ 331,073</u>
<b>Reconciliation of GAAP to Non-GAAP selling, general and administrative:</b>				
GAAP Selling, general and administrative	\$ 169,984	\$ 145,323	\$ 324,455	\$ 292,182
Less: Stock-based compensation expenses	(19,833)	(18,992)	(37,509)	(50,307)
Non-GAAP Selling, general and administrative	<u>\$ 150,151</u>	<u>\$ 126,331</u>	<u>\$ 286,946</u>	<u>\$ 241,875</u>
<b>Reconciliation of GAAP to Non-GAAP operating loss:</b>				
GAAP Operating loss	\$ (191,686)	\$ (146,160)	\$ (338,418)	\$ (332,414)
Add: Stock-based compensation expenses	30,471	32,078	59,764	87,768
Non-GAAP Operating loss	<u>\$ (161,215)</u>	<u>\$ (114,082)</u>	<u>\$ (278,654)</u>	<u>\$ (244,646)</u>

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Revenue and Operating Expense Growth at Constant Exchange Rate (CER)\*

	June 30, 2022	
	Three Months Ended	Six Months Ended
ONPATTRO net product revenue growth, as reported	35 %	35 %
Less: Impact of foreign currency translation	7	6
ONPATTRO net product revenue growth at constant currency	42 %	41 %
GIVLAARI net product revenue growth, as reported	47 %	45 %
Less: Impact of foreign currency translation	6	5
GIVLAARI net product revenue growth at constant currency	53 %	50 %
OXLUMO net product revenue growth, as reported	(9)%	16 %
Less: Impact of foreign currency translation	5	6
OXLUMO net product revenue growth at constant currency	(4)%	22 %
Total net product revenue growth, as reported	33 %	35 %
Less: Impact of foreign currency translation	7	6
Total net product revenue growth at constant currency	40 %	41 %

Please note that the figures presented may not sum exactly due to rounding

\* Constant Exchange Rate (CER) representing growth calculated as if the exchange rates had remained unchanged from those used in the second quarter 2021. CER is a Non-GAAP measure.